Table 1.

Characteristics of studies on HOTAIR polymorphism and cancer risk

First author	Year	Country	Ethnicity	Source of control	Genotyping methods	Type of cancers	Case	Control	Included in meta-analysis
Zhang [21]	2014	china	Asian	PB	RFLP	ESCC	1000	1000	Yes
Bayram [33]	2015	Turkey	Caucasian	HB	TaqMan	BC	123	122	Yes
Bayram [28]	2015	Turkey	Caucasian	HB	TaqMan	GC	104	209	Yes
Du [29]	2015	china	Asian	HB	Taqman	GC	753	1057	Yes
Guo [25]	2015	china	Asian	PB	RFLP	GCA	515	654	Yes
Xue [22]	2015	china	Asian	HB	Taqman	CRC	1147	1203	Yes
Yan [31]	2015	china	Asian	PB	RFLP	BC	502	504	Yes
Bayram [19]	2016	Turkey	Caucasian	HB	TaqMan	BC	123	122	Yes
Guo [32]	2016	china	Asian	HB	MALDI-TOF-MS	CC	510	713	Yes
Pan [26]	2016	china	Asian	PB	RFLP	GC	500	1000	Yes
Qiu [18]	2016	china	Asian	HB	Taqman	Ovarian cancer	190	380	No
Qiu [24]	2016	china	Asian	NA	Taqman	CC	215	430	No
Wu [30]	2016	china	Asian	NA	MALDI-TOF-MS	EOC	1000	1000	Yes
Zhou [38]	2016	china	Asian	HB	MALDI-TOF-MS	Osteosarcoma	500	500	Yes
Zhu [34]	2016	china	Asian	NA	RFLP	PTC	1000	1000	Yes
Hu [36]	2017	china	Asian	PB	TaqMan	Pancreatic cancer	416	416	Yes
Jin [27]	2017	china	Asian	HB	TaqMan	CC	1174	1304	Yes
Taheri [37]	2017	Iran	Caucasian	HB	ARMS-PCR	Prostate cancer	128	250	Yes
Ulger [23]	2017	Turkey	Caucasian	HB	TaqMan	GC	105	207	Yes
Xavier‑Magalhaes [35]	2017	Portugal	Caucasian	PB	RFLP	Glioma	177	199	Yes

BC Breast cancer, CRC Colorectal cancer, CC Cervical cancer, ESCC Esophageal squamous cell carcinoma, GC Gastric cancer, GCA Gastric cardia denocarcinoma, PTC Papillary thyroid carcinoma, HB Hospital-based, PB Population-based, RFLP restriction fragment length polymorphism, MOLDI-TOF-MS Matrix-Assisted Laser Desorption/ Ionization Time of Flight Mass Spectrometry